Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Clinical trial NCT00585377 · COMPLETED
Trial details
- NCT number
- NCT00585377
- Sponsor
- University of Utah
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-08-01
- Primary completion
- 2013-05-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.